Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4144 in Hepatic Impairment
NCT07783308Phase 1Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of AZD4144 (4 arms), sponsored by AstraZeneca. Primary endpoints: Area under the plasma concentration-time curve from zero to infinity, Area under the plasma concentration-time curve from zero to the last quantifiable concentration and 2 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
AZD4144
Beyond the preview
Go deeper on NCT07783308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783308.